<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23173749</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2012</Year><Month>Nov</Month><Day>23</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>A new treatment for neurogenic inflammation caused by EV71 with CR2-targeted complement inhibitor.</ArticleTitle><Pagination><StartPage>285</StartPage><MedlinePgn>285</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1743-422X-9-285</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Enterovirus 71 (EV71), one of the most important neurotropic EVs, has caused death and long-term neurological sequelae in hundreds of thousands of young children in the Asia-Pacific region in the past decade. The neurological diseases are attributed to infection by EV71 inducing an extensive peripheral and central nervous system (CNS) inflammatory response with abnormal cytokine production and lymphocyte depletion induced by EV71 infection. In the absence of specific antiviral agents or vaccines, an effective immunosuppressive strategy would be valuable to alleviate the severity of the local inflammation induced by EV71 infection.</AbstractText><AbstractText Label="PRESENTATION OF THE HYPOTHESIS" NlmCategory="OBJECTIVE">The complement system plays a pivotal role in the inflammatory response. Inappropriate or excessive activation of the complement system results in a severe inflammatory reaction or numerous pathological injuries. Previous studies have revealed that EV71 infection can induce complement activation and an inflammatory response of the CNS. CR2-targeted complement inhibition has been proved to be a potential therapeutic strategy for many diseases, such as influenza virus-induced lung tissue injury, postischemic cerebral injury and spinal cord injury. In this paper, a mouse model is proposed to test whether a recombinant fusion protein consisting of CR2 and a region of Crry (CR2-Crry) is able to specifically inhibit the local complement activation induced by EV71 infection, and to observe whether this treatment strategy can alleviate or even cure the neurogenic inflammation.</AbstractText><AbstractText Label="TESTING THE HYPOTHESIS" NlmCategory="METHODS">CR2-Crry is expressed in CHO cells, and its biological activity is determined by complement inhibition assays. 7-day-old ICR mice are inoculated intracranially with EV71 to duplicate the neurological symptoms. The mice are then divided into two groups, in one of which the mice are treated with CR2-Crry targeted complement inhibitor, and in the other with phosphate-buffered saline. A group of mice deficient in complement C3, the breakdown products of which bind to CR2, are also infected with EV71 virus. The potential bioavailability and efficacy of the targeted complement inhibitor are evaluated by histology, immunofluorescence staining and radiolabeling.</AbstractText><AbstractText Label="IMPLICATIONS OF THE HYPOTHESIS" NlmCategory="CONCLUSIONS">CR2-Crry-mediated targeting complement inhibition will alleviate the local inflammation and provide an effective treatment for the severe neurological diseases associated with EV71 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Shaofu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Disease Control and Prevention, Academy of Military Medical Sciences, Beijing, China. hongbinsong@263.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Nan</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Leili</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Guang</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Wenli</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Lixue</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chaojie</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chuanfu</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhongqiang</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Fei</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Tomlinson</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Atkinson</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yansong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Liuyu</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Hongbin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhenjun</ForeName><Initials>Z</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>11</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001688">Biological Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C081470">Cr1l protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011951">Receptors, Complement</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017463">Receptors, Complement 3b</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017464">Receptors, Complement 3d</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001688" MajorTopicYN="N">Biological Products</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020078" MajorTopicYN="N">Neurogenic Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011951" MajorTopicYN="N">Receptors, Complement</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017463" MajorTopicYN="N">Receptors, Complement 3b</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017464" MajorTopicYN="N">Receptors, Complement 3d</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>11</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23173749</ArticleId><ArticleId IdType="pmc">PMC3558417</ArticleId><ArticleId IdType="doi">10.1186/1743-422X-9-285</ArticleId><ArticleId IdType="pii">1743-422X-9-285</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang SM, Liu CC. Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther. 2009;7:735&#x2013;742. doi: 10.1586/eri.09.45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/eri.09.45</ArticleId><ArticleId IdType="pubmed">19681701</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CS, Yao YC, Lin SC, Lee YP, Wang YF, Wang JR, Liu CC, Lei HY, Yu CK. Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. J Virol. 2007;81:8996&#x2013;9003. doi: 10.1128/JVI.00236-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00236-07</ArticleId><ArticleId IdType="pmc">PMC1951457</ArticleId><ArticleId IdType="pubmed">17567704</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng KF, Chen LL, Huang PN, Shih SR. Neural pathogenesis of enterovirus 71 infection. Microbes Infect. 2010;12:505&#x2013;510. doi: 10.1016/j.micinf.2010.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2010.03.006</ArticleId><ArticleId IdType="pubmed">20348010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Chang LY. Development of enterovirus 71 vaccines. Expert Rev Vaccines. 2010;9:149&#x2013;156. doi: 10.1586/erv.09.152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.09.152</ArticleId><ArticleId IdType="pubmed">20109026</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallet S, Legrand Quillien MC, Dailland T, Podeur G, Gouriou S, Schuffenecker I, Payan C, Marcorelles P. Fatal case of enterovirus 71 infection, France, 2007. Emerg Infect Dis. 2009;15:1837&#x2013;1840. doi: 10.3201/eid1511.090493.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1511.090493</ArticleId><ArticleId IdType="pmc">PMC2857235</ArticleId><ArticleId IdType="pubmed">19891879</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Chen W, Chang H, Tang R, Zhao J, Gan L, Liu B, Chen J, Wang M. Genetic analysis of the VP1 region of enterovirus 71 reveals the emergence of genotype A in central China in 2008. Virus Genes. 2010;41:1&#x2013;4. doi: 10.1007/s11262-010-0472-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11262-010-0472-9</ArticleId><ArticleId IdType="pubmed">20306124</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JF, Cao RY, Jiang T, Yu M, Liu W, Tian X, Qin ED, Cao WC, Qin CF. Echovirus 30 in EV71-associated hand, foot and mouth disease outbreak, Guangxi, China. J Clin Virol. 2011;50:348&#x2013;349. doi: 10.1016/j.jcv.2011.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2011.01.005</ArticleId><ArticleId IdType="pubmed">21306942</ArticleId></ArticleIdList></Reference><Reference><Citation>Bible JM, Pantelidis P, Chan PK, Tong CY. Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol. 2007;17:371&#x2013;379. doi: 10.1002/rmv.538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.538</ArticleId><ArticleId IdType="pubmed">17487831</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;26:91&#x2013;107. doi: 10.1111/j.1574-6976.2002.tb00601.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia CS, Liu JN, Li WB, Ma CM, Lin SZ, Hao Y, Gao XZ, Liu XL, Xu YF, Zhang LF, Qin C. The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments. Virol J. 2010;7:47. doi: 10.1186/1743-422X-7-47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-47</ArticleId><ArticleId IdType="pmc">PMC2839975</ArticleId><ArticleId IdType="pubmed">20170551</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Huang KJ, Wu JM, Wang JR, Yu CK, Su IJ, Liu CC. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis. 2003;188:564&#x2013;570. doi: 10.1086/376998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/376998</ArticleId><ArticleId IdType="pubmed">12898444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TC, Guo HR, Su HJ, Yang YC, Chang HL, Chen KT. Diseases caused by enterovirus 71 infection. Pediatr Infect Dis J. 2009;28:904&#x2013;910. doi: 10.1097/INF.0b013e3181a41d63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e3181a41d63</ArticleId><ArticleId IdType="pubmed">20118685</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Chang LY, Huang YC, Hsu KH, Chiu CH, Yang KD. Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: implications for early recognition and therapy. Acta Paediatr. 2002;91:632&#x2013;635. doi: 10.1111/j.1651-2227.2002.tb03292.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1651-2227.2002.tb03292.x</ArticleId><ArticleId IdType="pubmed">12162592</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Hsia SH, Huang YC, Wu CT, Chang LY. Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis. 2003;36:269&#x2013;274. doi: 10.1086/345905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/345905</ArticleId><ArticleId IdType="pubmed">12539066</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Su LY, Wu JM, Yu CK, Wang JR, Liu CC. Cerebrospinal fluid cytokines in enterovirus 71 brain stem encephalitis and echovirus meningitis infections of varying severity. Clin Microbiol Infect. 2007;13:677&#x2013;682. doi: 10.1111/j.1469-0691.2007.01729.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2007.01729.x</ArticleId><ArticleId IdType="pubmed">17441979</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Yu CK, Wang JR, Su IJ, Liu CC. Acute chemokine response in the blood and cerebrospinal fluid of children with enterovirus 71-associated brainstem encephalitis. J Infect Dis. 2008;198:1002&#x2013;1006. doi: 10.1086/591462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/591462</ArticleId><ArticleId IdType="pubmed">18710325</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785&#x2013;797. doi: 10.1038/ni.1923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1923</ArticleId><ArticleId IdType="pmc">PMC2924908</ArticleId><ArticleId IdType="pubmed">20720586</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Xu Y, Jia L, Yang Y, Wang Y, Sun Y, Huang L, Qiao F, Tomlinson S, Liu X. et al.A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitor. Virol J. 2010;7:30. doi: 10.1186/1743-422X-7-30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-30</ArticleId><ArticleId IdType="pmc">PMC2829536</ArticleId><ArticleId IdType="pubmed">20144216</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjoberg AP, Trouw LA, Blom AM. Complement activation and inhibition: a delicate balance. Trends Immunol. 2009;30:83&#x2013;90. doi: 10.1016/j.it.2008.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2008.11.003</ArticleId><ArticleId IdType="pubmed">19144569</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopf M, Abel B, Gallimore A, Carroll M, Bachmann MF. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med. 2002;8:373&#x2013;378. doi: 10.1038/nm0402-373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0402-373</ArticleId><ArticleId IdType="pubmed">11927943</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson DR, Carthy CM, Wilson JE, Yang D, Devine DV, McManus BM. Complement component 3 interactions with coxsackievirus B3 capsid proteins: innate immunity and the rapid formation of splenic antiviral germinal centers. J Virol. 1997;71:8841&#x2013;8845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192350</ArticleId><ArticleId IdType="pubmed">9343244</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih SR, Stollar V, Lin JY, Chang SC, Chen GW, Li ML. Identification of genes involved in the host response to enterovirus 71 infection. J Neurovirol. 2004;10:293&#x2013;304. doi: 10.1080/13550280490499551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13550280490499551</ArticleId><ArticleId IdType="pubmed">15385252</ArticleId></ArticleIdList></Reference><Reference><Citation>Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058&#x2013;1066. doi: 10.1056/NEJM200104053441406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200104053441406</ArticleId><ArticleId IdType="pubmed">11287977</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H, He C, Knaak C, Guthridge JM, Holers VM, Tomlinson S. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest. 2003;111:1875&#x2013;1885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC161422</ArticleId><ArticleId IdType="pubmed">12813023</ArticleId></ArticleIdList></Reference><Reference><Citation>Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344:1140&#x2013;1144. doi: 10.1056/NEJM200104123441506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200104123441506</ArticleId><ArticleId IdType="pubmed">11297706</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson C, Song H, Lu B, Qiao F, Burns TA, Holers VM, Tsokos GC, Tomlinson S. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest. 2005;115:2444&#x2013;2453. doi: 10.1172/JCI25208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI25208</ArticleId><ArticleId IdType="pmc">PMC1190375</ArticleId><ArticleId IdType="pubmed">16127466</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao F, Atkinson C, Song H, Pannu R, Singh I, Tomlinson S. Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol. 2006;169:1039&#x2013;1047. doi: 10.2353/ajpath.2006.060248.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2006.060248</ArticleId><ArticleId IdType="pmc">PMC1698827</ArticleId><ArticleId IdType="pubmed">16936276</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson C, Zhu H, Qiao F, Varela JC, Yu J, Song H, Kindy MS, Tomlinson S. Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol. 2006;177:7266&#x2013;7274.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082645</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol. 2008;181:8068&#x2013;8076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782395</ArticleId><ArticleId IdType="pubmed">19017999</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>